Mantle Cell Lymphoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Suspended
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022B
Recruiting
- B-cell Malignancy, Low-grade
- +4 more
- Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai JiaoTong University School of Medicine
2022-04-05
Apr 5, 2022M
Active, not recruiting
- Mantle Cell Lymphoma
- Cyclophosphamide
- +8 more
- Houston, TexasM D Anderson Cancer Center
2022-04-05
Apr 5, 2022A
Not yet recruiting
- Follicular Lymphoma
- +2 more
- ClonoSEQ
- Palo Alto, CaliforniaStanford Cancer Center
2022-04-04
Apr 4, 2022H
Recruiting
- Mantle Cell Lymphoma
- Busan, Western, Korea, Republic ofKosin University Gospel Hospital
2022-03-31
Mar 31, 2022W
Active, not recruiting
- Mantle Cell Lymphoma
- lenalidomide
- rituximab
- Tampa, Florida
- +3 more
2022-03-26
Mar 26, 2022Q
Recruiting
- Follicular Lymphoma
- +7 more
- Louisville, Kentucky
- +4 more
2022-03-11
Mar 11, 2022I
Recruiting
- Non-Hodgkin Lymphoma
- +4 more
- Duarte, California
- +12 more
2022-03-24
Mar 24, 2022N
Completed
- Mantle Cell Lymphoma
- Lymphoma, Mantle Cell
- EPOCH-R
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-24
Mar 24, 2022J
Enrolling by invitation
- Chronic Lymphocytic Leukemia
- +6 more
- Duarte, California
- +165 more
2022-03-24
Mar 24, 2022J
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +3 more
- Tucson, Arizona
- +202 more
2022-03-24
Mar 24, 2022C
Active, not recruiting
- Adult Immunoblastic Lymphoma
- +12 more
- Cytology Specimen Collection Procedure
- Birmingham, Alabama
- +129 more
2022-03-23
Mar 23, 2022A
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +7 more
- New Orleans, Louisiana
- +3 more
2022-03-22
Mar 22, 2022T
Active, not recruiting
- Diffuse Large B-Cell Lymphoma
- +4 more
- Ublituximab
- +2 more
- Birmingham, Alabama
- +167 more
2022-03-22
Mar 22, 2022U
Recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- R-CHOP chemotherapy
- Vancouver, British Columbia, Canada
- +3 more
2022-03-17
Mar 17, 2022T
Recruiting
- Mantle Cell Lymphoma
- Ibrutinib 560 mg
- +3 more
- Bruges, Belgium
- +39 more
2022-03-03
Mar 3, 2022F
Recruiting
- Acute Leukemia
- +18 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022F
Recruiting
- Acute Biphenotypic Leukemia
- +18 more
- Cyclophosphamide
- +8 more
- Aurora, Colorado
- +2 more
2022-03-02
Mar 2, 2022J
Not yet recruiting
- B-Cell Lymphoma
- +8 more
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
- Pittsburgh, PennsylvaniaAHN Cancer Institute - West Penn Hospital
2022-03-08
Mar 8, 2022A
Active, not recruiting
- Lymphoma, B-Cell
- +8 more
- Scottsdale, Arizona
- +9 more
2022-03-10
Mar 10, 2022S
Terminated
- Mantle Cell Lymphoma
- Mainz, Germany
- +18 more
2022-02-24
Feb 24, 2022M
Active, not recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +3 more
- Cyclophosphamide
- +10 more
- Houston, TexasM D Anderson Cancer Center
2022-03-08
Mar 8, 2022B
Recruiting
- Mantle Cell Lymphoma
- +9 more
- L-Bcl-2 antisense oligonucleotide
- Augusta, Georgia
- +2 more
2022-03-08
Mar 8, 2022C
U
Recruiting
- Mantle Cell Lymphoma
- +2 more
- Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
2022-03-07
Mar 7, 2022